WO2006009480A1 - A computer system, computer executable instructions and method for data extraction and analysis - Google Patents
A computer system, computer executable instructions and method for data extraction and analysis Download PDFInfo
- Publication number
- WO2006009480A1 WO2006009480A1 PCT/NZ2005/000183 NZ2005000183W WO2006009480A1 WO 2006009480 A1 WO2006009480 A1 WO 2006009480A1 NZ 2005000183 W NZ2005000183 W NZ 2005000183W WO 2006009480 A1 WO2006009480 A1 WO 2006009480A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- data
- entity
- customers
- customer
- information
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
Definitions
- the present invention relates to a method of data extraction, and analysis, and in particular, though not solely, to a method of extracting and analysing marketing and/or promotional activity data from a plurality of business entities.
- Products companies which rely on the sale of goods and/or services (hereinafter referred to as "products") to generate revenue often direct resources (such as labour and funding) into marketing and promoting those products to a customer base, which may include actual existing customers and/or prospective future customers.
- resources such as labour and funding
- the key parameters or performance indicators may include the total contacts made between sales representatives and customers and/or the customer segments, the percentage of customers contacted by sales representatives in a defined period and the frequency of the contact and the share of voice (that is, the number of contacts made by that company in a particular segment as a percentage of total contacts in that segment).
- customer panel data to provide competing companies with data about their own and their competitor's marketing and promotional activity.
- the customer panel is a select group of customers who provide feedback on contact they have had from each company.
- this type of data does not accurately represent market activity as the "customer panel” is only a sample of the total customer population.
- the data obtained does not enable differentiation of customers based on a particular company's defined segments.
- ETMS electronic territory management systems
- Such systems comprise some form of database to collect sales force and marketing activity through a user interface and usually also provide some reporting functionality for the data stored in the database.
- Prior art ETMS's are currently supplied as industry standard software suites from vendors such as Seibel, Dendrite and Stay In Front. These commercial products are designed for use by a single company or a group of companies which have their own business rules for structuring data.
- Such ETMS's are not adapted to rationalise data from different organisations with different business rules and data frameworks, which is a disadvantage.
- matching relates to identifying customers, or such like, which are related in common to two or more sets of data.
- contacts refers to contact made including, but not limited to, calls, visits, emails, letters, and such like.
- calls As used herein the terms “calls”, “called on”, and such like, are intended to have a meaning which includes telephone calls, in person calls. As used herein the term “segments” used in relation to customers and such like is intended to refer to any grouping of customers.
- isolation is intended to refer to a relationship where participation of or communication or data from an entity is not required.
- data structure is intended to refer broadly to any arrangement of data including tables, and tabulated data structures.
- master list refers to a list held by the third entity of the customers, for example, of the other entities which allows referencing of the customers independently of lists or identifiers provided by those entities.
- the master list is useful for cross-referencing the lists provided by each entity.
- the invention may broadly be said to consist in a method of analysing data for a first entity having a sales force and/or marketing resource, comprising the steps of:
- first data including information on promotional activity related to a plurality of customers of said first entity, wherein the first data includes a ranking of importance of customers to the first entity;
- the method includes the step of matching each customer in the first data with that same customer in the second data.
- the matching includes creating a third party master list of customers of the first and second entities.
- the method includes the step of inputting first and second data into a common data structure.
- the common data structure comprises a join table which provides cross- referencing of individual customers of the first or second entities.
- the data structure includes match references for the same customers of each entity, whereby given customers are capable of being referenced independently of identifiers used by the first or second entities.
- the method includes inputting additional data from one or more additional entities, each having respective sales forces and/or marketing resources, said additional data including information on promotional activity related to a plurality of customers of the respective entity wherein the respective data includes a ranking of importance of customers to the respective entity and includes the step of comparing said information on promotional activity on a customer-by-customer basis and the step of outputting a result of said comparison of said information on promotional activity.
- the promotional activity data includes, information on the number of contacts made with given customers.
- the promotional activity data includes information on the number of contacts made with given customers in different time periods.
- the result includes the proportion of the total calls made by the first and any other entity to their customers.
- contacts made with a given customer comprise calls.
- the result includes the percentage of the customers that have been called on by the first entity and by other entities.
- the result includes the average frequency that customers were called on by the first entity and any other entity in a defined time period.
- the ranking of importance provided to customers by an entity comprises an allocation of given customers of that entity to one of a predetermined number of customer segments, each segment having a different ranking of importance to that entity.
- the result includes the proportion of the total calls made to a customer segment of the first entity by the second and/or any subsequent entity.
- the method is carried out in isolation of the first entity.
- the customer ranking information within any respective entity's data is not shared with any other entity.
- the step of outputting includes the step of ordering the result by the customer ranking of importance applied by the first entity.
- the data input from each entity also includes geographical location information for given customer.
- the step of outputting includes the step of ordering the result by geographic location and then by customer ranking according to the first entity.
- the data input from each entity includes promotional activity for given customers in relation to a plurality of different products.
- the step of outputting includes the step of ordering the result by product and then by customer ranking according to the first entity.
- said given customers may include all customers of the entity.
- the present invention may broadly be said to consist in a set of computer executable instructions stored on a computer readable medium which carries out the method according to the first aspect.
- the present invention may broadly be said to consist in a computer system for analysing data for a first entity having a sales force and/or marketing resource, said system comprising:
- first entity means for inputting first data from the first entity, said first data including information on promotional activity to each of a plurality of customers of said first entity, wherein each customer in the first data includes a ranking of importance of customers to the first entity;
- ii) means for inputting second data from a second entity having a sales force and/or marketing resource, said second data providing information on promotional activity to each of a plurality of customers of said second entity, wherein the second data includes a ranking of importance of customers to the second entity and wherein at least one customer is in common to the first and second entities;
- iii) means for comparing said information on promotional activity for the first entity with said information on promotional activity data for the second entity on a customer-by-customer basis;
- iv) means for outputting a result of the comparison of said information on promotional activity.
- the computer system is adapted to match each customer in the first data with that same customer in the second data.
- Figure 1 is a flow diagram illustrating the steps involved in a method of extracting and analysing data in accordance with a preferred embodiment of the present invention
- Figure 2 is a graphical representation of a sample database table generated by apparatus configured to perform the method as summarised in Figure 1 subsequent to receiving and inputting raw data from various entities, and
- Figure 3 is a graphical representation of a sample report generated by apparatus configured to perform the method as summarised in
- FIG. 1 a schematic flow diagram illustrating the steps involved in a method of extracting and analysing data in accordance with a preferred embodiment of the present invention is shown.
- the present invention is particularly suited for extracting and analysing data from a plurality of entities, and more particularly, entities having respective sales forces and/or promotional activity who supply goods and/or services (hereinafter "products") to customers.
- product goods and/or services
- an entity may be an individual, group of individuals and/or a business organisation.
- pharmaceutical manufacturing companies for illustrative purposes only reference throughout this specification will be made to the entities being pharmaceutical manufacturing companies although this should in no way be seen as limiting as the applicants envisage that the present invention may be equally and effectively applied across a range of industries, such as photocopier sales or in the banking and/or insurance industries.
- the third party entity is independent of any of the entities supplying data and is unable to share data between entities.
- the initial step 1 involves establishing the terms upon which the entity or entities (hereinafter "pharmaceutical companies") agree to supply sales and/or promotional data to the third party entity.
- the data will normally be supplied to the third party entity under terms of strict confidentially.
- the pharmaceutical companies are agreeing to allow the sales data to be used in a manner which will result in its eventual disclosure to their competitors in an aggregated and de-identified (or masked) format.
- the process by which such data is extracted, aggregated and de-identified and subsequently presented to the pharmaceutical companies will now be described.
- the third party entity will utilise appropriate known software executed on a computing system to create a database having the required table structure and field definitions to enable data received from the pharmaceutical companies to be stored and easily accessible.
- the software is used to create a set of a predefined data rules applicable to the tables and fields defined within the database. Accordingly, the software run by the computing system associated with the third party entity will be adapted to generate a database adapted to receive actual data from each of the contributing pharmaceutical companies, rather than survey data from for example, a sample panel of respondents.
- Each pharmaceutical company may however have its own set of business rules regarding how data is to be classified into each of these tables.
- the constituent base tables of the database may be similar for each of the contributing pharmaceutical companies and each table will comprise key elements such as a doctor list (that is, the list of doctors to whom the pharmaceutical company has supplied or wishes to supply pharmaceuticals to), a territory structure and information on sales or promotional activity for each doctor.
- a doctor list that is, the list of doctors to whom the pharmaceutical company has supplied or wishes to supply pharmaceuticals to
- territory structure information on sales or promotional activity for each doctor.
- a territory structure refers to a geographical area which has been assigned to a particular sales representative(s) (working for a pharmaceutical company) for marketing and promoting sales of products manufactured and sold by a specific pharmaceutical company.
- each customer has at least an associated territory, a customer identifier, an indication of one or more products which are of interest to that customer, a ranking of importance to the pharmaceutical company and promotional activity data with that customer (such as dates on which calls were made to that customer and the product(s) which were promoted).
- Raw data is preferably requested from the pharmaceutical companies by the third party entities and subsequently extracted (indicated as step 2 in Figure 1) from the pharmaceutical companies' "ETMS".
- an ETMS may include some form of database adapted to collect territory based sales data.
- Such raw sales data may be supplied to the third party entity from each company's ETMS in any number of a variety of data formats.
- the data may be extracted and supplied in comma delimited flat files (CSV), Microsoft Access database (mdb) and/or detached SQL server database (mdf) files.
- CSV comma delimited flat files
- mdb Microsoft Access database
- mdf detached SQL server database
- the data may be imported into the third party entity database via standard database connectivity and data transformation applications. If the pharmaceutical company's data (which will typically be in the form of data tables) does not follow the format specified by the third party entity then changes may be made to the format of the data to enable flawless and accurate data transfer.
- the validation process comprises a series of checks which are performed to ensure data consistency, quality and fitness for its purpose. For example, data received may have missing or incorrectly labelled fields and/or missing or incomplete data tables.
- Initial visual data validation checks may be conducted by the third party entity personnel to ensure general accuracy of the data.
- a variety of automated checks or balances may then or instead be conducted to establish the total number of customers (that is, the doctors) of the pharmaceutical company, the addresses of the customers, the number of territories in which the pharmaceutical company is operational and the number of customer profiles by product (sold by the pharmaceutical company).
- combinatorial checks may also be conducted including (but not limited to) the total number of customers and customer addresses attributable to each territory, the total number of calls within a specific time period (that is, the number of times a sales representative for a specific pharmaceutical company has contacted (such as by phone, e-mail and/or physically visited) a customer in order to market the company's product), the total number of calls made by sales representatives by product, the total number of details by product and/or the total number of calls attributed to each territory.
- the results of these counts are preferably appended to a validation result table.
- the purpose of the validation table(s) is to provide a customer specific reference list against which all data which is extracted in the future can be compared to establish data confidence level or levels.
- the validation result table is then compared to a source table which contains details regarding expected counts and suggested acceptable variances for each actual count conducted.
- Each actual count is compared against expected or anticipated count values to give a variance.
- the variance may be signalled if it is outside a permitted or predetermined acceptable variance (such as 5%) to indicate a requirement for investigation to justify the differences or to correct the data.
- step 3 in Figure 1 After the data has been validated it is necessary for it to be refined (shown as step 3 in Figure 1) to ensure its accuracy.
- Each pharmaceutical company's sales database(s) is typically being continually updated with new customer details and changes in existing customer's details. Accordingly, each company's database(s) may ordinarily comprise a mixture of current accurate data, out of date data and missing data.
- Data duplication may also occur resulting in the same customer having different customer identifiers (such as customer identification number), or a single customer having more than one address.
- Data may become outdated as a result of customers moving location or changing name. Missing data may arise due to a failure by sales representatives of the specific pharmaceutical company to adequately record customer activity. Accordingly, it is necessary for such erroneous data to be fixed, excluded, or otherwise normalised. Normalisation involves amending data which has been supplied in an incorrect or incompatible format (or data which requires conversion from a non-industry standard data) to industry standard format.
- the refining process may be configured to exclude data that does not conform to the specific pharmaceutical company's own set of rules which have been agreed previously with the third party entity.
- the third party entity In order for the third party entity to analyse data provided by the pharmaceutical companies it must build and maintain a join table in order to cross reference each company's individual customer lists against the third party's own master listing of all customers. Although any given industry (such as the pharmaceutical industry) may have providers of syndicated customer lists, the majority of companies will use a particular customer identification schema which is unique to their own organisation. In this regard the third party entity may utilise a computing system adapted to execute stored procedures (such as a software program in SQL or other query based programming language) that suggests matches between the same customers on different company lists based on field matching combinations derived from the company's own database.
- stored procedures such as a software program in SQL or other query based programming language
- Such a provision will enable all activity to be reported to each pharmaceutical company at a customer level, irrespective of the specific customer identifier given by any one of the participating pharmaceutical companies (and/or their associated ETMS's).
- geographic structures such as address or location
- other key parameters could be used to suggest matches between the same customers on different company lists.
- the refined data is placed in a tabulated format having a common structure, or data structure, which aggregates each company's unique products, calls, structure and segments by dimensions of time, product, segment, location and activity.
- a common structure or data structure
- Such an aggregation will produce tables of results for each pharmaceutical company based on their own activity with respect to their own customers versus that of their competitors' activity with respect to the first mentioned pharmaceutical company's customers.
- the tables will enable the third party entity to have data from multiple pharmaceutical companies in a single structure or format but yet create unique results for each individual pharmaceutical company.
- FIG. 2 shows a graphical representation of an example of such a table 7 configured in accordance with a preferred embodiment of the present invention.
- table 7 Shown in table 7 is a column or field 9 which illustrates a unique identifier named CRMS MatchlD which is allocated to each customer of any pharmaceutical company (in the example shown there are three entities or pharmaceutical companies named Companies A-C in column or field 8).
- Companies A-C Each customer (such as a doctor), of each of the pharmaceutical companies, will typically have a unique identifier which uniquely identifies it to a specific pharmaceutical company).
- pharmaceutical company "Company A” has allocated CustomerlD "AD243GH7" to one of its customers.
- pharmaceutical company "Company B” has allocated CustomerlD "1020335" to that same doctor.
- the third party entity creates a master or source list of identifiers or keys which are adapted to identify identical customers having different CustomerlD's in the various source datas.
- the third party entity has assigned CRMS MatchlD "2203042" to the customer (or doctor) independently known as CustomerlD "AD243GH7", “1020335” and "GPOBYT” by the companies A, B and C respectively.
- each pharmaceutical company will also typically associate with each customer a segment identifier which may be used to classify or rank each customer by value or worth of the customer to the specific pharmaceutical company.
- a pharmaceutical company's best or most highly valued customers may be known as “Gold” or "High” or “1” category customers whereas a pharmaceutical company's neutral or low value customers may be known as “Bronze” or "Low” or “3 " category customers.
- the customer having CRMS MatchlD "2203042" has been placed in a customer segment "Green” by "Company A", customer segment “1” by “Company B” and customer segment “Low” by “Company C”. There may not necessarily be any overlap between Company A's
- Each company will define and name their sales territories independently of one another and there is not necessarily any overlap in defining these parameters.
- the customer having CustomerlD "AD243GH7" (and a CRMS MatchlD "2203042”) has been assigned a territory identifier "203" (as shown in column 11) by Company A.
- that same doctor has been assigned a territory identifier "Tty55” by Company B.
- territory "203" of Company A overlaps in some way with territory “Tty55” of Company B but that is all that can be determined.
- the column immediately to the right of column 11. describes a field labelled "State” which indicates the State of Australia within which the customer is positioned. This physical territorial information may be input directly as part of the raw input data or may be determined by the data refinement process 3.
- Call activity by each pharmaceutical company may then be mapped against each customer (shown as columns or fields 12).
- the number of calls made to each specific customer by sales representatives of a pharmaceutical company may be recorded as a rolling or moving annual total, that is, the total number of calls made to each specific customer in the 12 month period preceding the specific reporting date (shown as CallCountMAT in Figure 2), a moving 6 monthly total, that is, the total number of calls made to each specific customer in the 6 month period preceding the specific reporting date (shown as CallCount 6mo in Figure 2) and/or a moving 3 monthly total, that is, the total number of calls made to each specific customer in the 3 month period preceding the specific reporting date (shown as CallCount Qtr in Figure 2).
- the present invention preferably utilises a customisable reporting software package to generate a plurality of reports (shown as step 5 in Figure 1).
- reports may be in the form of physical (paper) and/or soft copy reports which may be used by personnel to analyse the data contained in the table(s) (one of which is shown by way of example in Figure 2).
- each company will be provided with at least one report which comprises data sourced from a common data pool contained within the table(s) generated in accordance with step 4 of Figure 1.
- each individual company will receive a personalised report which presents the common data in a manner which is compatible with its own specific predefined definitions and rankings.
- FIG 3 is a graphical representation of an example report 13 generated in accordance with the present invention.
- a report 13 shows a particular pharmaceutical company's own promotional or calling activity against their own customers and the promotional or calling activity of their competitors against these same customers.
- Such calling activity may be shown at a national, regional or local level and may also be divided into categories by customer type. For example, if the customer is a doctor then that broad category of customer may be further divided into sub-categories including specialists and general practitioners provided that this information is included in the raw data from companies.
- the sub-category indicating the customer type may alternatively or in addition be reported according to a territory or specific geographical category.
- Such call activity may be grouped according to a specific pharmaceutical company's own unique segment and territory definitions.
- the accumulated call activity for a specific time period according to an aggregation of all companies' call activity can also be shown for these categories.
- each pharmaceutical company will see call activity by all competing companies against customers in its own segment, but will not see how other companies have grouped those customers.
- the data is analysed to provide key performance parameters such as the proportion of the total calls made by a specific company to their customer population (shown in Figure 3 as "SOV” or Share of Voice and indicated by reference numeral 14), the percentage of a specific pharmaceutical company's total customer population or segment population that has been called on at least once by themselves and by competitor pharmaceutical companies (shown in Figure 3 as “Call Coverage” and indicated by reference numeral 15), how frequently, on average that the customers that were called on by a pharmaceutical company at least once were actually called on (shown in Figure 3 as "Frequency” and indicated by reference numeral 16) and the proportion of the total calls made by each pharmaceutical company to customers in each specific customer defined segment (shown in Figure 3 as "SOE” or Share of Effort and indicated by reference numeral 17).
- a pharmaceutical company's own specific geographical groups may have results presented in a graphical format to enable easier and faster comparison between their performance and that of their competing companies over a time period. That is, although Figure 3 shows a "National" overview of promotional activity, a further report may be generated which is limited to a specific geographical region (such as the State of New South Wales) and the data may be presented graphically (such as by bar graph rather than numerically as in Figure 3).
- Each report may preferably include a summary of the total calls made by each company over a plurality of time periods.
- a report may include a total count of customers which the viewing company (that is, the specific pharmaceutical company to which the report is directed - "Viewing Company" in Figure 3) knows about, as well as a count of customers which each of the competing companies knows about (are represented in their input data).
- the number of customers which each of the competing pharmaceutical companies have in their input data which the viewing pharmaceutical company does not have in their input data may also be reported to the viewing company.
- Such parameters may be adapted to draw a viewer's attention to the fact that there may be customers which the viewing pharmaceutical company does not know about which its competitors may be directing a significant portion of their sales effort towards.
- Figure 3 includes annual, previous six months and previous quarter results so that changes and trends are easily disclosed.
- the results may also show that if the proportion of the total calls made by a specific company to a specific customer segment appears to be increasing over a period of time a conclusion that the company was increasingly viewing this segment as comprising high value customers and was consequently directing increasing proportions of its effort towards them could be reached. Depending on how the viewing company ranked this segment group (such as high value, medium value or low value) it may take such a finding as a warning to increase its own sales effort toward this segment.
- the viewing company may elect to increase its own calling capacity for the specific geographic region, or alternatively reduce its sales effort directed at lower ranked customers in order to direct more effort at the higher ranked customers in that geographic region.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ53429804 | 2004-07-22 | ||
NZ534298 | 2004-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006009480A1 true WO2006009480A1 (en) | 2006-01-26 |
Family
ID=35785499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NZ2005/000183 WO2006009480A1 (en) | 2004-07-22 | 2005-07-22 | A computer system, computer executable instructions and method for data extraction and analysis |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006009480A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012154977A1 (en) * | 2011-05-10 | 2012-11-15 | Ims Health Incorporated | Analytic services portal |
US20130006711A1 (en) * | 2011-06-30 | 2013-01-03 | Infosys Limited | System and method for enhancing productivity of sales and marketing operations of pharmaceutical companies |
US8417560B2 (en) | 2008-04-18 | 2013-04-09 | Steven Woods | Systems, methods, and apparatus for analyzing the influence of marketing assets |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5930764A (en) * | 1995-10-17 | 1999-07-27 | Citibank, N.A. | Sales and marketing support system using a customer information database |
-
2005
- 2005-07-22 WO PCT/NZ2005/000183 patent/WO2006009480A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5930764A (en) * | 1995-10-17 | 1999-07-27 | Citibank, N.A. | Sales and marketing support system using a customer information database |
Non-Patent Citations (1)
Title |
---|
JACKSON D.R.: "Next generation marketing", DIRECT MARKETING, GARDEN CITY, vol. 58, no. 11, March 1996 (1996-03-01), pages 25 - 28 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8417560B2 (en) | 2008-04-18 | 2013-04-09 | Steven Woods | Systems, methods, and apparatus for analyzing the influence of marketing assets |
WO2012154977A1 (en) * | 2011-05-10 | 2012-11-15 | Ims Health Incorporated | Analytic services portal |
CN103814389A (en) * | 2011-05-10 | 2014-05-21 | Ims保健公司 | Analytic services portal |
US9916590B2 (en) | 2011-05-10 | 2018-03-13 | Quintiles Ims Incorporated | Analytic services portal |
US20130006711A1 (en) * | 2011-06-30 | 2013-01-03 | Infosys Limited | System and method for enhancing productivity of sales and marketing operations of pharmaceutical companies |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tompa et al. | A systematic review of occupational health and safety interventions with economic analyses | |
Lerner et al. | Relationship of employee-reported work limitations to work productivity | |
Chakraborty et al. | Measuring consumer satisfaction in health care sector: the applicability of servqual | |
Henshall et al. | Priority setting for health technology assessment: Theoretical considerations and practical approaches: A paper produced by the priority setting subgroup of the EUR-ASSESS project | |
US8341101B1 (en) | Determining relationships between data items and individuals, and dynamically calculating a metric score based on groups of characteristics | |
Mukamel et al. | Nursing homes' response to the nursing home compare report card | |
Koehlmoos et al. | The effect of social franchising on access to and quality of health services in low‐and middle‐income countries | |
KR20160002760A (en) | Systems and methods for market participant-based automated decisioning | |
WO2006133290A2 (en) | Method and apparatus for managing information sets related to administering medical care to one or more patients | |
US20060129447A1 (en) | Methods and software arrangements for sales force effectiveness | |
US20140297366A1 (en) | Scaled subscriber profile groups for emarketers | |
CA2810205A1 (en) | User list identification | |
Walker et al. | A universal framework for the benefit-risk assessment of medicines: is this the way forward? | |
Koh et al. | Health as a way of doing business | |
Szász et al. | How do companies lose orders? A multi-country study of internal inconsistency in operations strategies | |
US8234154B2 (en) | System and method for pharmaceutical geographic market segmentation | |
Kuutila et al. | Reviewing literature on time pressure in software engineering and related professions: computer assisted interdisciplinary literature review | |
Pedan et al. | Asymmetric responsiveness of physician prescription behavior to drug promotion of competitive brands within an established therapeutic drug class | |
WO2005048036A2 (en) | System and method for correlating market research data based on sales representative activity | |
WO2006009480A1 (en) | A computer system, computer executable instructions and method for data extraction and analysis | |
US20130006711A1 (en) | System and method for enhancing productivity of sales and marketing operations of pharmaceutical companies | |
US20050114171A1 (en) | System and method for correlating market research data based on attitude information | |
Garcia-Buendia et al. | Mapping the lean supply chain management research through citation classics | |
Rein et al. | Establishing a vision and eye health surveillance system for the nation: a status update on the vision and eye health surveillance system | |
US20210158919A1 (en) | Medical processing systems and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05764499 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1)EPC |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05764499 Country of ref document: EP Kind code of ref document: A1 |